Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

161. Infliximab treatment in inflammatory bowel disease does not increase the risk of malignancy

Publication date: 18/10/2017 Abstract Authors’ conclusions: exposure to infliximab is not associated with an increased risk of malignancy or hemophagocytic syndrome in children with inflammatory bowel disease. Exposure to thiopurines is an important antecedent for the development of these complications. Reviewers’ commentary: the use of infliximab and other biological therapies does not seem to increase the risk of onset of tumors in the medium term, although it would be advisable to prolong the follow-up (...) Infliximab treatment in inflammatory bowel disease does not increase the risk of malignancy Infliximab treatment in inflammatory bowel disease does not increase the risk of malignancy - Evidencias en pediatría Searching, please wait Show menu Library Management You did not add any article to your library yet. | Search Evidence-Based decision making Evidence-Based decision making Show menu Library Management You did not add any article to your library yet. × User Password Log in × Reset password

2018 Evidencias en Pediatría

162. Management of rectal gastrointestinal stromal tumor Full Text available with Trip Pro

Management of rectal gastrointestinal stromal tumor Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. However, rectal GIST is rare, the incident rate of it is approximately 5% of all GISTs. Rectal GIST symptoms generally include bleeding and/or pain and occasionally, urinary symptoms. Immunohistochemical evaluation finds that most rectal GIST tumors are CD117 (KIT) positive, and are sometimes CD34, platelet-derived growth factor (...) receptor alpha (PDGFRA), smooth muscle actin, S-100, or vimentin positive. The National Institutes of Health (NIH) classifies rectal GIST as very-low risk, low risk, intermediate risk, or high risk, and the frequencies have been estimated as 0-23.8% for very-low risk, 0-45% for low risk, 0-34% for intermediate risk, and 21-100% for high risk tumors. The first-line treatment for localized GIST is curative resection, but is difficult in rectal GIST because of anatomical characteristics such as the deep

2018 Translational gastroenterology and hepatology

163. Lonsurf for Metastatic Colorectal Cancer – Details

Lonsurf for Metastatic Colorectal Cancer – Details Lonsurf for Metastatic Colorectal Cancer – Details | CADTH.ca Find the information you need Lonsurf for Metastatic Colorectal Cancer – Details Lonsurf for Metastatic Colorectal Cancer – Details Project Number pCODR 10122 Brand Name Lonsurf Generic Name Trifluridine and Tipiracil Strength 15 mg & 20 mg Tumour Type Gastrointestinal Indication Metastatic Colorectal Cancer Funding Request For the treatment of adult patients with metastatic (...) colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date January 25, 2018 Manufacturer Taiho Pharma Canada, Inc. Submitter Taiho Pharma Canada, Inc. Submission Date November 6, 2017 Submission Deemed Complete November 13, 2017 Submission Type New Drug

2018 CADTH - Pan Canadian Oncology Drug Review

164. Microsatellite instability in colorectal cancer Full Text available with Trip Pro

as the presence of alternate sized repetitive DNA sequences which are not present in the corresponding germ line DNA. The presence of MSI is found in sporadic colon, gastric, sporadic endometrial and the majority of other cancers. Approximately, 15-20 % of colorectal cancers display MSI. Determination of MSI status in CRC has prognostic and therapeutic implications. As well, detecting MSI is used diagnostically for tumor detection and classification. For these reasons, microsatellite instability analysis (...) Microsatellite instability in colorectal cancer Colorectal cancer (CRC) is a heterogeneous disease that is caused by the interaction of genetic and environmental factors. Although it is one of the most common cancers worldwide, CRC would be one of the most curable cancers if it is detected in the early stages. Molecular changes that occur in colorectal cancer may be categorized into three main groups: 1) Chromosomal Instability (CIN), 2) Microsatellite Instability (MSI), and 3) CpG Island

2018 EXCLI journal

165. Gastrointestinal stromal tumor of the esophagus: current issues of diagnosis, surgery and drug therapy Full Text available with Trip Pro

Gastrointestinal stromal tumor of the esophagus: current issues of diagnosis, surgery and drug therapy Gastrointestinal stromal tumors (GISTs) often arise in the stomach and small intestine, while esophageal GISTs are rare. Due to their rarity, clinicopathological data on esophageal GISTs are extremely limited, and this results in a lack of clear recommendations concerning optimal surgical management for esophageal GISTs. It is difficult to distinguish esophageal GIST from leiomyoma, the most (...) frequent esophageal mesenchymal tumor, prior to resection, because the two types of tumors appear similar on computed tomography (CT), endoscopic ultrasound (EUS), and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). Fine-needle aspiration biopsy (FNAB) under EUS enables definitive diagnosis, but it is often avoided because scarring could make enucleation more difficult and increase the risk of tumor dissemination by capsule destruction. Esophageal segmental and wedge resections

2018 Translational gastroenterology and hepatology

166. Vectibix for Left Sided Metastatic Colorectal Cancer — Details

Vectibix for Left Sided Metastatic Colorectal Cancer — Details Vectibix for Left Sided Metastatic Colorectal Cancer – Details | CADTH.ca Find the information you need Vectibix for Left Sided Metastatic Colorectal Cancer – Details Vectibix for Left Sided Metastatic Colorectal Cancer – Details Project Number pCODR 10118 Brand Name Vectibix Generic Name Panitumumab Strength 20 mg/mL Tumour Type Gastrointestinal Indication Left Sided Metastatic Colorectal Cancer Funding Request In combination (...) with chemotherapy, for the first-line treatment of mCRC patients with left sided primary tumours that express wild-type RAS Review Status Notification to Implement Issued Pre Noc Submission No NOC Date August 31, 2015 Manufacturer Amgen Canada Inc. Submitter Amgen Canada Inc. Submission Date September 8, 2017 Submission Deemed Complete September 15, 2017 Submission Type New Indication Prioritization Requested Not Requested Stakeholder Input Deadline ‡ September 22, 2017 Check-point meeting October 30, 2017 pERC

2018 CADTH - Pan Canadian Oncology Drug Review

167. Erbitux for Left Sided Metastatic Colorectal Cancer – Details

Erbitux for Left Sided Metastatic Colorectal Cancer – Details Erbitux for Left Sided Metastatic Colorectal Cancer – Details | CADTH.ca Find the information you need Erbitux for Left Sided Metastatic Colorectal Cancer – Details Erbitux for Left Sided Metastatic Colorectal Cancer – Details Project Number pCODR 10128 Brand Name Erbitux Generic Name Cetuximab Strength 2 mg/mL Tumour Type Gastrointestinal Indication Left Sided Metastatic Colorectal Cancer Funding Request For the first-line treatment (...) of RAS wild-type metastatic colorectalcarcinoma (mCRC) patients with left sided primary tumours Review Status File-Closed Not Submitted Clarification The submitter notified pCODR that they will not be filing the submission. Pre Noc Submission No NOC Date September 9, 2005 Manufacturer Eli Lilly Canada Inc. Submitter Eli Lilly Canada Inc. Submission Date (Target Date) Submission Type New Indication Prioritization Requested Stakeholder Input Deadline (target date based on target submission date

2018 CADTH - Pan Canadian Oncology Drug Review

168. Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma' by Rosati et al. Full Text available with Trip Pro

Colonic Neoplasms Colorectal Neoplasms Humans 2016 1 27 6 0 2016 1 27 6 0 2018 1 19 6 0 ppublish 26811349 mdw039 10.1093/annonc/mdw039 (...) Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma' by Rosati et al. 26811349 2018 01 18 2018 12 02 1569-8041 27 5 2016 05 Annals of oncology : official journal of the European Society for Medical Oncology Ann. Oncol. Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma' by Rosati et al. 957-8

2018 Annals of oncology : official journal of the European Society for Medical Oncology Controlled trial quality: uncertain

169. Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma' by Hines et al. Full Text available with Trip Pro

di Ricerche Farmacologiche Mario Negri, Milan roldano.fossati@marionegri.it. eng Letter Comment 2016 02 23 England Ann Oncol 9007735 0923-7534 0 Carcinoembryonic Antigen IM Ann Oncol. 2016 Feb;27(2):274-80 26578734 Ann Oncol. 2016 May;27(5):957-8 26811349 Carcinoembryonic Antigen Colonic Neoplasms Colorectal Neoplasms Humans 2016 2 26 6 0 2016 2 26 6 0 2018 1 19 6 0 ppublish 26912556 mdw076 10.1093/annonc/mdw076 (...) Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma' by Hines et al. 26912556 2018 01 18 2018 12 02 1569-8041 27 6 2016 06 Annals of oncology : official journal of the European Society for Medical Oncology Ann. Oncol. Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma' by Hines et al. 1171

2018 Annals of oncology : official journal of the European Society for Medical Oncology Controlled trial quality: uncertain

170. Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case Full Text available with Trip Pro

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case Constitutive activation of HER2-dependent intracellular signalling by HER2 gene amplification or by HER2 mutations has been demonstrated as a mechanism of primary and secondary cancer resistance to cetuximab or panitumumab in preclinical and clinical models of metastatic colorectal cancer (mCRC). Both HER2 Amplification for Colorectal (...) Cancer Enhanced Stratification (HERACLES) cohort A and My Pathway clinical trials provided clinical evidence that anti-HER2 therapies could be active in these patients.HER2 gene amplification and HER2 protein overexpression analysis were performed in tumour tissue by fluorescence in situ hybridisation and immunohistochemistry. HER2 positivity was defined according to HERACLES CRC-specific HER2 scoring criteria. DNA analysis for multiple assessment of gene mutations or amplifications was carried out

2018 ESMO open

171. Neoadjuvant therapy for gastrointestinal stromal tumor Full Text available with Trip Pro

Neoadjuvant therapy for gastrointestinal stromal tumor Molecular-targeting therapy using tyrosine kinase inhibitor imatinib mesylate is effective for metastasis/recurrent gastrointestinal stromal tumors (GISTs). Likewise, imatinib would be effective in the neoadjuvant therapy for high-risk GIST. Neoadjuvant therapy may have the potential to increase the complete resection rate and to avoid the surgical rupture by decreasing the tumor size. Thereby, it is expected that improvement of recurrence (...) rate and survival rate can be obtained by neoadjuvant therapy. Neoadjuvant therapy is also expected to be favored from the viewpoint of organ/function preservation by tumor shrinkage. The existing results of clinical trials established the feasibility of neoadjuvant imatinib therapy. However, proof of the survival effectiveness of neoadjuvant imatinib therapy has not been sufficiently demonstrated. The aim of this article is to introduce previous evidence and strategies regarding neoadjuvant

2018 Translational gastroenterology and hepatology

172. Molecular characterization and pathogenesis of gastrointestinal stromal tumor Full Text available with Trip Pro

Molecular characterization and pathogenesis of gastrointestinal stromal tumor Most gastrointestinal stromal tumors (GISTs) harbor activating mutations in the receptor tyrosine kinase gene KIT or platelet-derived growth factor receptor alpha (PDGFRA), and the resultant activation of downstream signals plays a pivotal role in the development of GISTs. The sites of the tyrosine kinase gene mutations are associated with the biological behavior of GISTs, including risk category, clinical outcome (...) and drug response. Mutations in RAS signaling pathway genes, including KRAS and BRAF, have also been reported in KIT/PDGFRA wild-type GISTs, though they are rare. Neurofibromin 1 (NF1) is a tumor suppressor gene mutated in neurofibromatosis type 1. Patients with NF1 mutations are at high risk of developing GISTs. Recent findings suggest that altered expression or mutation of members of succinate dehydrogenase (SDH) heterotetramer are causally associated with GIST development through induction

2018 Translational gastroenterology and hepatology

173. Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies Full Text available with Trip Pro

gastrointestinal GI malignancies and the emerging data on immune biomarkers and SBRT, with a focus on pancreatic and liver cancer. (...) Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies The role of external beam radiation therapy (EBRT) in the management of upper gastrointestinal malignancies is constantly evolving. As radiation therapy techniques improve and are able to deliver more ablative doses of radiotherapy while sparing healthy tissue, radiation can be applied to a wider range of clinical scenarios. Stereotactic body radiation therapy (SBRT) allows a high dose of radiation to be delivered

2018 Biomedicines

174. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Full Text available with Trip Pro

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. ARCHER 1042, a randomized phase II trial, explored the impact of prophylactic treatment on select dermatologic adverse events of interest (SDAEI), diarrhea, and mucositis associated with dacomitinib, an oral irreversible pan-human epidermal growth factor receptor (HER) inhibitor, in development for advanced non-small (...) -cell lung cancer (NSCLC).Patients with advanced NSCLC treated with dacomitinib were enrolled in two cohorts. Cohort I patients were randomized 1:1 to receive oral doxycycline or placebo (4 weeks). Cohort II patients received oral VSL#3 probiotic plus topical alclometasone. Primary end points for Cohorts I and II were incidence of all grade and grade ≥2 SDAEI in the first 8 weeks of treatment and quality of life (QoL) assessed by the Skindex-16 survey. Additional primary end points for Cohort II

2018 Annals of oncology : official journal of the European Society for Medical Oncology Controlled trial quality: uncertain

175. Primary care: Faecal immunochemical tests have the potential for correctly ruling out colorectal cancer in symptomatic patients

care Faecal immunochemical tests have the potential for correctly ruling out colorectal cancer in symptomatic patients Carlo Senore 1 , Ulrike Haug 2 , 3 Statistics from Altmetric.com Commentary on: Westwood M, Lang S, Armstrong N, et al . Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance. BMC Med 2017 Oct 24;15:189. Context Efforts (...) aimed to increase awareness of colorectal cancer (CRC) symptoms and to reduce the proportion of cases diagnosed following an emergency presentation might result in a substantial increase in the demand for diagnostic colonoscopies, exceeding the available endoscopy capacity. The aim of this systematic review was to analyse the diagnostic performance of quantitative faecal immunochemical test (FIT) as a triage test for patients with lower abdominal symptoms. 1 Methods This is a review of diagnostic

2018 Evidence-Based Medicine

176. Revised Australian national guidelines for colorectal cancer screening: family history

Revised Australian national guidelines for colorectal cancer screening: family history Revised Australian national guidelines for colorectal cancer screening: family history | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down (...) Individual Login Purchase options menu search Advertisement close Revised Australian national guidelines for colorectal cancer screening: family history Mark A Jenkins, Driss Ait Ouakrim, Alex Boussioutas, John L Hopper, Hooi C Ee, Jon D Emery, Finlay A Macrae, Albert Chetcuti, Laura Wuellner and D James B St John Med J Aust 2018; 209 (10): . || doi: 10.5694/mja18.00142 Published online: 29 October 2018 Topics Abstract Introduction: Screening is an effective means for colorectal cancer prevention

2018 MJA Clinical Guidelines

177. Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. Full Text available with Trip Pro

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. 29718089 2018 12 20 1569-8041 29 11 2018 Nov 01 Annals of oncology : official journal of the European Society for Medical Oncology Ann. Oncol. Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. 2270 10.1093

2018 Annals of oncology : official journal of the European Society for Medical Oncology Controlled trial quality: uncertain

178. Consensus and controversies regarding follow?up after curative intent treatment of non?metastatic colorectal cancer: a synopsis of guidelines used in countries represented in ESCP Full Text available with Trip Pro

Consensus and controversies regarding follow?up after curative intent treatment of non?metastatic colorectal cancer: a synopsis of guidelines used in countries represented in ESCP Consensus and controversies regarding follow‐up after treatment with curative intent of nonmetastatic colorectal cancer: a synopsis of guidelines used in countries represented in the European Society of Coloproctology - Bastiaenen - 2019 - Colorectal Disease - Wiley Online Library By continuing to browse this site (...) , you agree to its use of cookies as described in our . Search within Search term Search term Systematic Review Consensus and controversies regarding follow‐up after treatment with curative intent of nonmetastatic colorectal cancer: a synopsis of guidelines used in countries represented in the European Society of Coloproctology Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands Corresponding Author E-mail address: Department of Surgery, Aarhus University

2018 Palliative Care Evidence Review Service (PaCERS)

179. Colorectal cancer

, radiotherapy, resection of metastases) has increased survival in selected cases. Definition The majority of colorectal cancers are adenocarcinomas derived from epithelial cells. About 71% of new colorectal cancers arise in the colon and 29% in the rectum. Toms JR, ed. CancerStats monograph 2004. London: Cancer Research; 2004. Less common types of malignant colorectal tumours are carcinoid tumours, GI stromal cell tumours, and lymphomas. Increasing age is the greatest risk factor for sporadic colorectal (...) adenocarcinoma with 99% of cancers occurring in people aged 40 years or over. History and exam presence of risk factors increasing age rectal bleeding change in bowel habit rectal mass positive FHx abdominal mass anaemia male sex abdominal pain weight loss and anorexia abdominal distension palpable lymph nodes increasing age APC mutation Lynch syndrome (HNPCC) MYH-associated polyposis hamartomatous polyposis syndromes inflammatory bowel disease obesity acromegaly limited physical activity lack of dietary

2018 BMJ Best Practice

180. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Full Text available with Trip Pro

Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation January 2018 Article Contents Article Navigation Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS T Yoshino Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center (...) rates and/or a large tumour size reduction (shrinkage) is recommended [II, A]. 13b. There is uncertainty surrounding the best combination to use as only a few trials have addressed this specifically: • In patients with RAS wt disease a cytotoxic doublet plus an anti-EGFR antibody seems to have the best benefit risk/ratio, although the combination of FOLFOXIRI plus or minus bevacizumab may also be considered and, to a lesser extent, a cytotoxic doublet plus bevacizumab [II, A] • In patients with RAS

2018 European Society for Medical Oncology